Review

Department of Otolaryngology & Head & Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, MD, USA

† Author for correspondence

Search for more papers by this author

Email the corresponding author at mhoque1@jhmi.edu

Published Online:11 Aug 2010https://doi.org/10.2217/bmm.10.72

View article

Abstract

Ovarian cancer is the leading cause of death among gynecological cancers. It is now recognized that in addition to genetic alterations, epigenetic mechanisms, such as DNA methylation, histone modifications and nucleosome remodeling, play an important role in the development and progression of ovarian cancer by modulating chromatin structure, and gene and miRNA expression. Furthermore, epigenetic alterations have been recognized as useful tools for the development of novel biomarkers for diagnosis, prognosis, therapeutic prediction and monitoring of diseases. Moreover, new epigenetic therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been found to be a potential therapeutic option, especially when used in combination with other agents. Here we discuss current developments in ovarian carcinoma epigenome research, the importance of the ovarian carcinoma epigenome for development of diagnostic and prognostic biomarkers, and the current epigenetic therapies used in ovarian cancer.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

1 Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. (2010) (Epub ahead of print).
MedlineGoogle Scholar
2 Jones PA, Laird PW: Cancer epigenetics comes of age. Nat. Genet.21(2),163–167 (1999).
Medline CASGoogle Scholar
3 Barakat RR, Markman M, Randall M: Principles and Practice Of Gynecologic Oncology (5^th Edition). Wolters Kluwer/Lippincott Williams & Wilkins, PA, USA (2009).
Google Scholar
4 Barton CA, Hacker NF, Clark SJ, O’Brien PM: DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol. Oncol.109(1),129–139 (2008).▪▪ Very complete review of epigenetic changes in ovarian cancer and their importance in the detection of biomarkers for diagnosis, prognosis and therapeutic response.
Medline CASGoogle Scholar
5 Baylin SB, Ohm JE: Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer6(2),107–116 (2006).▪▪ Interesting article on how epigenetic alterations drive cells to certain pathways that lead to tumorigenesis.
Medline CASGoogle Scholar
6 Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet.8(4),286–298 (2007).▪▪ Comprehensive review of the techniques used for the study of the DNA methylome and histone modifications, emphasizing genome-wide arrays.
Medline CASGoogle Scholar
7 Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.3(6),415–428 (2002).▪▪ Excellent article on epigenetic mechanisms that alter the expression of genes.
Medline CASGoogle Scholar
8 Ting AH, McGarvey KM, Baylin SB: The cancer epigenome – components and functional correlates. Genes Dev.20(23),3215–3231 (2006).
Medline CASGoogle Scholar
9 Jones PA, Baylin SB: The epigenomics of cancer. Cell128(4),683–692 (2007).
Medline CASGoogle Scholar
10 Richardson BC: Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J. Nutr.132(Suppl. 8),2401S–2405S (2002).
Medline CASGoogle Scholar
11 Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science300(5618),455 (2003).
Medline CASGoogle Scholar
12 Feinberg AP, Tycko B: The history of cancer epigenetics. Nat. Rev. Cancer4(2),143–153 (2004).▪ Traces epigenetic alterations since their conception and reviews the advances made on this field, addressing the genetic basis of epigenetic changes.
Medline CASGoogle Scholar
13 Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene21(35),5400–5413 (2002).
Medline CASGoogle Scholar
14 Martin C, Zhang Y: The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol.6(11),838–849 (2005).▪▪ Summarizes the recent advances in the understanding of how lysine methylation plays an important role in heterochromatin formation and transcriptional regulation.
Medline CASGoogle Scholar
15 Esteller M, Almouzni G: How epigenetics integrates nuclear functions. Workshop on epigenetics and chromatin: transcriptional regulation and beyond. EMBO Rep.6(7),624–628 (2005).
Medline CASGoogle Scholar
16 Nguyen CT, Gonzales FA, Jones PA: Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res.29(22),4598–4606 (2001).
Medline CASGoogle Scholar
17 Knudson AG: Chasing the cancer demon. Annu. Rev. Genet.34,1–19 (2000).
Medline CASGoogle Scholar
18 Nussbaum RL, Mcinnes RR, Willard HF, Thompson MW: Thompson & Thompson Genetics in Medicine (7^th Edition). Saunders/Elsevier, PA, USA (2007).
Google Scholar
19 Antequera F, Bird A, Jost IJP, Saluz: DNA Methylation: Molecular Biology and Biological Significance. Birkhauser Verlag, Basel, Switzerland, 169–185 (1993).
Google Scholar
20 Takai D, Jones PA: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. Sci. USA99(6),3740–3745 (2002).
Medline CASGoogle Scholar
21 Ferguson-Smith AC, Surani MA: Imprinting and the epigenetic asymmetry between parental genomes. Science293(5532),1086–1089 (2001).
Medline CASGoogle Scholar
22 Reik W, Lewis A: Co-evolution of X-chromosome inactivation and imprinting in mammals. Nat. Rev. Genet.6(5),403–410 (2005).
Medline CASGoogle Scholar
23 Brenner C, Fuks F: DNA methyltransferases: facts, clues, mysteries. Curr. Top. Microbiol. Immunol.301,45–66 (2006).
Medline CASGoogle Scholar
24 Tajima S, Suetake I: Regulation and function of DNA methylation in vertebrates. J. Biochem.123(6),993–999 (1998).
Medline CASGoogle Scholar
25 Okano M, Bell DW, Haber DA, Li E: DNA methyltransferases DNMT3A and DNMT3B are essential for de novo methylation and mammalian development. Cell99(3),247–257 (1999).
Medline CASGoogle Scholar
26 Chedin F, Lieber Mr, Hsieh Cl: The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by DNMT3A. Proc. Natl Acad. Sci. USA99(26),16916–16921 (2002).
Medline CASGoogle Scholar
27 Aapola U, Kawasaki K, Scott HS et al.: Isolation and initial characterization of a novel zinc finger gene, DNMT3l, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family. Genomics65(3),293–298 (2000).
Medline CASGoogle Scholar
28 Dong A, Yoder JA, Zhang X, Zhou L, Bestor TH, Cheng X: Structure of human DNMT2, an enigmatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA. Nucleic Acids Res.29(2),439–448 (2001).
Medline CASGoogle Scholar
29 Schaefer M, Lyko F: Solving the DNMT2 enigma. Chromosoma119(1),35–40 (2010).
Medline CASGoogle Scholar
30 Sinkkonen L, Hugenschmidt T, Berninger P et al.: MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nat. Struct. Mol. Biol.15(3),259–267 (2008).
Medline CASGoogle Scholar
31 Benetti R, Gonzalo S, Jaco I et al.: A mammalian microRNA cluster controls DNA methylation and telomere recombination via RBL2-dependent regulation of DNA methyltransferases. Nat. Struct. Mol. Biol.15(9),998 (2008).
Medline CASGoogle Scholar
32 Kim VN: MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol.6(5),376–385 (2005).
Medline CASGoogle Scholar
33 Ehrlich M: DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J. Nutr.132(Suppl. 8),2424S–2429S (2002).
Medline CASGoogle Scholar
34 Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature301(5895),89–92 (1983).
Medline CASGoogle Scholar
35 Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. Nature395(6697),89–93 (1998).
Medline CASGoogle Scholar
36 Kaneda A, Feinberg AP: Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res.65(24),11236–11240 (2005).
Medline CASGoogle Scholar
37 Kornberg RD, Lorch Y: Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell98(3),285–294 (1999).
Medline CASGoogle Scholar
38 Schubeler D, Macalpine DM, Scalzo D et al.: The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev.18(11),1263–1271 (2004).
MedlineGoogle Scholar
39 Shiio Y, Eisenman RN: Histone sumoylation is associated with transcriptional repression. Proc. Natl Acad. Sci. USA100(23),13225–13230 (2003).
Medline CASGoogle Scholar
40 Shilatifard A: Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Ann. Rev. Biochem.75,243–269 (2006).
Medline CASGoogle Scholar
41 Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G: Genome regulation by polycomb and trithorax proteins. Cell128(4),735–745 (2007).
Medline CASGoogle Scholar
42 Cao R, Wang L, Wang H et al.: Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science298(5595),1039–1043 (2002).
Medline CASGoogle Scholar
43 Fuks F, Hurd Pj, Deplus R, Kouzarides T: The DNA methyltransferases associate with hp1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res.31(9),2305–2312 (2003).
Medline CASGoogle Scholar
44 Lachner M, O’Carroll D, Rea S, Mechtler K, Jenuwein T: Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature410(6824),116–120 (2001).
Medline CASGoogle Scholar
45 Clouaire T, Stancheva I: Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? Cell Mol. Life Sci.65(10),1509–1522 (2008).
Medline CASGoogle Scholar
46 Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T: The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem.278(6),4035–4040 (2003).
Medline CASGoogle Scholar
47 Jones PL, Veenstra GJ, Wade PA et al.: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet.19(2),187–191 (1998).
Medline CASGoogle Scholar
48 Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell116(2),281–297 (2004).
Medline CASGoogle Scholar
49 Boehm M, Slack FJ: MicroRNA control of lifespan and metabolism. Cell Cycle5(8),837–840 (2006).
Medline CASGoogle Scholar
50 Carleton M, Cleary MA, Linsley PS: MicroRNAs and cell cycle regulation. Cell Cycle6(17),2127–2132 (2007).
Medline CASGoogle Scholar
51 Harfe BD: MicroRNAs in vertebrate development. Curr. Opin. Genet. Dev.15(4),410–415 (2005).
Medline CASGoogle Scholar
52 Lau NC, Lim LP, Weinstein EG, Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science294(5543),858–862 (2001).
Medline CASGoogle Scholar
53 Lu J, Getz G, Miska EA et al.: MicroRNA expression profiles classify human cancers. Nature435(7043),834–838 (2005).
Medline CASGoogle Scholar
54 Volinia S, Calin GA, Liu CG et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA103(7),2257–2261 (2006).
Medline CASGoogle Scholar
55 Calin GA, Dumitru CD, Shimizu M et al.: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA99(24),15524–15529 (2002).
Medline CASGoogle Scholar
56 Calin GA, Ferracin M, Cimmino A et al.: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med.353(17),1793–1801 (2005).
Medline CASGoogle Scholar
57 Nakamura T, Canaani E, Croce CM: Oncogenic ALL1 fusion proteins target drosha-mediated microRNA processing. Proc. Natl Acad. Sci. USA104(26),10980–10985 (2007).
Medline CASGoogle Scholar
58 Saito Y, Liang G, Egger G et al.: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell9(6),435–443 (2006).
Medline CASGoogle Scholar
59 Chang TC, Wentzel EA, Kent OA et al.: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell.26(5),745–752 (2007).
Medline CASGoogle Scholar
60 He L, He X, Lim LP et al.: A microRNA component of the p53 tumour suppressor network. Nature447(7148),1130–1134 (2007).
Medline CASGoogle Scholar
61 Raver-Shapira N, Marciano E, Meiri E et al.: Transcriptional activation of mir-34a contributes to p53-mediated apoptosis. Mol. Cell.26(5),731–743 (2007).
Medline CASGoogle Scholar
62 Sellar GC, Watt KP, Rabiasz GJ et al.: OPCMl at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat. Genet.34(3),337–343 (2003).
Medline CASGoogle Scholar
63 Teodoridis JM, Hall J, Marsh S et al.: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res.65(19),8961–8967 (2005).
Medline CASGoogle Scholar
64 Zhang J, Ye F, Chen HZ, Ye DF, Lu WG, Xie X: [Deletion of OPCMl gene and promoter methylation in ovarian epithelial carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao28(2),173–177 (2006).
MedlineGoogle Scholar
65 Kwong J, Lee JY, Wong KK et al.: Candidate tumor suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia8(4),268–278 (2006).
Medline CASGoogle Scholar
66 Agathanggelou A, Honorio S, Macartney DP et al.: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene20(12),1509–1518 (2001).
Medline CASGoogle Scholar
67 Ibanez De Caceres I, Battagli C, Esteller M et al.: Tumor cell-specific brca1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res.64(18),6476–6481 (2004).▪ Important article showing that promoter hypermethylation can be detected in bodily fluids of patients with ovarian cancer, enhancing its early detection.
MedlineGoogle Scholar
68 Rathi A, Virmani AK, Schorge JO et al.: Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin. Cancer Res.8(11),3324–3331 (2002).
Medline CASGoogle Scholar
69 Yoon JH, Dammann R, Pfeifer GP: Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer94(2),212–217 (2001).
Medline CASGoogle Scholar
70 Petrocca F, Iliopoulos D, Qin HR et al.: Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res.66(21),10287–10291 (2006).
Medline CASGoogle Scholar
71 Yu Y, Fujii S, Yuan J et al.: Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann. NY Acad. Sci.983,268–277 (2003).
Medline CASGoogle Scholar
72 Yu Y, Xu F, Peng H et al.: NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl Acad. Sci. USA96(1),214–219 (1999).
Medline CASGoogle Scholar
73 Chien J, Staub J, Avula R et al.: Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene24(32),5089–5100 (2005).
Medline CASGoogle Scholar
74 Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res.61(8),3225–3229 (2001).▪ Interesting article showing cancer-specific methylation profiles, leading to important knowledge of the cancer epigenome.
Medline CASGoogle Scholar
75 Esteller M, Silva JM, Dominguez G et al.: Promoter hypermethylation and brca1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst.92(7),564–569 (2000).
Medline CASGoogle Scholar
76 Baldwin RL, Nemeth E, Tran H et al.: BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res.60(19),5329–5333 (2000).
Medline CASGoogle Scholar
77 Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US: Epigenetic factors controlling the brca1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res.62(14),4151–4156 (2002).
Medline CASGoogle Scholar
78 Wilcox CB, Baysal BE, Gallion HH, Strange MA, Deloia JA: High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet. Cytogenet.159(2),114–122 (2005).
Medline CASGoogle Scholar
79 Esteller M: Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur. J. Cancer36(18),2294–2300 (2000).
Medline CASGoogle Scholar
80 Gras E, Cortes J, Diez O et al.: Loss of heterozygosity on chromosome 13q12-q14, brca-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer92(4),787–795 (2001).
Medline CASGoogle Scholar
81 Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, Deyoung B, Buller RE: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl Cancer Inst.94(18),1396–1406 (2002).
Medline CASGoogle Scholar
82 Milde-Langosch K, Ocon E, Becker G, Loning T: P16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int. J. Cancer79(1),61–65 (1998).
Medline CASGoogle Scholar
83 Socha MJ, Said N, Dai Y et al.: Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia11(2),126–135 (2009).
Medline CASGoogle Scholar
84 Kikuchi R, Tsuda H, Kozaki K et al.: Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer. Cancer Res.68(13),5067–5075 (2008).
Medline CASGoogle Scholar
85 Kikuchi R, Tsuda H, Kanai Y et al.: Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res.67(15),7095–7105 (2007).
Medline CASGoogle Scholar
86 Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A: Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol. Oncol.95(3),449–455 (2004).
Medline CASGoogle Scholar
87 Pruitt K, Ulku AS, Frantz K et al.: Ras-mediated loss of the pro-apoptotic response protein PAR-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J. Biol. Chem.280(24),23363–23370 (2005).
Medline CASGoogle Scholar
88 Arnold JM, Cummings M, Purdie D, Chenevix-Trench G: Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br. J. Cancer85(9),1351–1358 (2001).
Medline CASGoogle Scholar
89 Yuecheng Y, Hongmei L, Xiaoyan X: Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin. Exp. Metastasis23(1),65–74 (2006).
MedlineGoogle Scholar
90 Feng W, Marquez RT, Lu Z et al.: Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer112(7),1489–1502 (2008).
Medline CASGoogle Scholar
91 Fiegl H, Windbichler G, Mueller-Holzner E et al.: HOXA11 DNA methylation – a novel prognostic biomarker in ovarian cancer. Int. J. Cancer123(3),725–729 (2008).
Medline CASGoogle Scholar
92 Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P: Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res.68(4),998–1002 (2008).
Medline CASGoogle Scholar
93 Izutsu N, Maesawa C, Shibazaki M et al.: Epigenetic modification is involved in aberrant expression of class III β-tubulin, TUBB3, in ovarian cancer cells. Int. J. Oncol.32(6),1227–1235 (2008).
Medline CASGoogle Scholar
94 Cheng P, Schmutte C, Cofer KF, Felix JC, Yu MC, Dubeau L: Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br. J. Cancer75(3),396–402 (1997).
Medline CASGoogle Scholar
95 Rose SL, Fitzgerald MP, White NO et al.: Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol. Oncol.102(2),319–324 (2006).
Medline CASGoogle Scholar
96 Czekierdowski A, Czekierdowska S, Wielgos M, Smolen A, Kaminski P, Kotarski J: The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-γ (sncg) in ovarian cancer. Neuro. Endocrinol. Lett.27(3),381–386 (2006).
Medline CASGoogle Scholar
97 Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J: Hypomethylation of the synuclein g gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res.63(3),664–673 (2003).
Medline CASGoogle Scholar
98 Honda H, Pazin MJ, Ji H, Wernyj RP, Morin PJ: Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J. Biol. Chem.281(30),21433–21444 (2006).
Medline CASGoogle Scholar
99 Litkouhi B, Kwong J, Lo CM et al.: Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia9(4),304–314 (2007).
Medline CASGoogle Scholar
100 Menendez L, Benigno BB, Mcdonald JF: L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol. Cancer3,12 (2004).
MedlineGoogle Scholar
101 Kolomietz E, Meyn MS, Pandita A, Squire JA: The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer35(2),97–112 (2002).
Medline CASGoogle Scholar
102 Symer DE, Connelly C, Szak St et al.: Human L1 retrotransposition is associated with genetic instability in vivo. Cell110(3),327–338 (2002).
Medline CASGoogle Scholar
103 Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR: DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun.7,21 (2007).
MedlineGoogle Scholar
104 Murphy SK, Huang Z, Wen Y et al.: Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol. Cancer Res.4(4),283–292 (2006).
Medline CASGoogle Scholar
105 Ahluwalia A, Hurteau JA, Bigsby RM, Nephew KP: DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol. Oncol.82(2),299–304 (2001).
Medline CASGoogle Scholar
106 Ehrlich M, Woods CB, Yu MC et al.: Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene25(18),2636–2645 (2006).
Medline CASGoogle Scholar
107 Chen CL, Yan X, Gao YN, Liao QP: [Expression of DNA methyltransferase 1, 3A and 3B mRNA in the epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi40(11),770–774 (2005).
MedlineGoogle Scholar
108 Kaneuchi M, Sasaki M, Tanaka Y et al.: Expression and methylation status of 14–3-3 s gene can characterize the different histological features of ovarian cancer. Biochem. Biophys. Res. Commun.316(4),1156–1162 (2004).
Medline CASGoogle Scholar
109 Kaneuchi M, Sasaki M, Tanaka Y et al.: WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer104(9),1924–1930 (2005).
Medline CASGoogle Scholar
110 Terasawa K, Sagae S, Toyota M et al.: Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin. Cancer Res.10(6),2000–2006 (2004).
Medline CASGoogle Scholar
111 Makarla PB, Saboorian MH, Ashfaq R et al.: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin. Cancer Res.11(15),5365–5369 (2005).
Medline CASGoogle Scholar
112 Caslini C, Capo-Chichi CD, Roland IH, Nicolas E, Yeung AT, Xu XX: Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene25(39),5446–5461 (2006).
Medline CASGoogle Scholar
113 Valls E, Sanchez-Molina S, Martinez-Balbas MA: Role of histone modifications in marking and activating genes through mitosis. J. Biol. Chem.280(52),42592–42600 (2005).
Medline CASGoogle Scholar
114 Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA97(18),10014–10019 (2000).
Medline CASGoogle Scholar
115 Chan MW, Huang YW, Hartman-Frey C et al.: Aberrant transforming growth factor-β1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia10(9),908–919 (2008).
Medline CASGoogle Scholar
116 Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA93(18),9821–9826 (1996).
Medline CASGoogle Scholar
117 Laird PW: The power and the promise of DNA methylation markers. Nat. Rev. Cancer3(4),253–266 (2003).
Medline CASGoogle Scholar
118 Rand KN, Ho T, Qu W et al.: Headloop suppression PCR and its application to selective amplification of methylated DNA sequences. Nucleic Acids Res.33(14),e127 (2005).
MedlineGoogle Scholar
119 Cottrell SE, Laird PW: Sensitive detection of DNA methylation. Ann. NY Acad. Sci.983,120–130 (2003).
Medline CASGoogle Scholar
120 Fraga MF, Esteller M: DNA methylation: a profile of methods and applications. Biotechniques33(3), 632, 634, 636–649 (2002).
Google Scholar
121 Bird AP, Southern EM: Use of restriction enzymes to study eukaryotic DNA methylation: I. The methylation pattern in ribosomal DNA from Xenopus laevis. J. Mol. Biol.118(1),27–47 (1978).
Medline CASGoogle Scholar
122 Frommer M, Mcdonald LE, Millar Ds et al.: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA89(5),1827–1831 (1992).
Medline CASGoogle Scholar
123 Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res.25(12),2532–2534 (1997).
Medline CASGoogle Scholar
124 Eads CA, Danenberg KD, Kawakami K et al.: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res.28(8),E32 (2000).
Medline CASGoogle Scholar
125 Fackler MJ, Mcveigh M, Mehrotra J et al.: Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res.64(13),4442–4452 (2004).
Medline CASGoogle Scholar
126 Swift-Scanlan T, Blackford A, Argani P, Sukumar S, Fackler MJ: Two-color quantitative multiplex methylation-specific PCR. Biotechniques40(2),210–219 (2006).
Medline CASGoogle Scholar
127 Tost J, Gut IG: DNA methylation analysis by pyrosequencing. Nat. Protoc.2(9),2265–2275 (2007).
Medline CASGoogle Scholar
128 Tost J, Gut IG: Analysis of gene-specific DNA methylation patterns by pyrosequencing technology. Methods Mol. Biol.373,89–102 (2007).
Medline CASGoogle Scholar
129 Costello JF, Fruhwald MC, Smiraglia DJ et al.: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet.24(2),132–138 (2000).
Medline CASGoogle Scholar
130 Huang TH, Perry MR, Laux DE: Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet.8(3),459–470 (1999).
Medline CASGoogle Scholar
131 Hoque MO, Kim MS, Ostrow KL et al.: Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res.68(8),2661–2670 (2008).
Medline CASGoogle Scholar
132 Suzuki H, Gabrielson E, Chen W et al.: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet.31(2),141–149 (2002).
Medline CASGoogle Scholar
133 Yamashita K, Upadhyay S, Osada M et al.: Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell2(6),485–495 (2002).
Medline CASGoogle Scholar
134 Frigola J, Ribas M, Risques RA, Peinado MA: Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res.30(7),e28 (2002).
MedlineGoogle Scholar
135 Toyota M, Ho C, Ahuja N et al.: Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res.59(10),2307–2312 (1999).
Medline CASGoogle Scholar
136 Khulan B, Thompson RF, Ye K et al.: Comparative isoschizomer profiling of cytosine methylation: the help assay. Genome Res.16(8),1046–1055 (2006).
Medline CASGoogle Scholar
137 Keshet I, Schlesinger Y, Farkash S et al.: Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat. Genet.38(2),149–153 (2006).
Medline CASGoogle Scholar
138 Weber M, Davies JJ, Wittig D et al.: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet.37(8),853–862 (2005).
Medline CASGoogle Scholar
139 Weber M, Hellmann I, Stadler MB et al.: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet.39(4),457–466 (2007).
Medline CASGoogle Scholar
140 Noushmehr H, Weisenberger DJ, Diefes K et al.: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell17(5),510–522 (2010).
Medline CASGoogle Scholar
141 Kuras L: Characterization of protein-DNA association in vivo by chromatin immunoprecipitation. Methods Mol. Biol.284,147–162 (2004).
Medline CASGoogle Scholar
142 Roh TY, Ngau WC, Cui K, Landsman D, Zhao K: High-resolution genome-wide mapping of histone modifications. Nat. Biotechnol.22(8),1013–1016 (2004).
Medline CASGoogle Scholar
143 Barski A, Cuddapah S, Cui K et al.: High-resolution profiling of histone methylations in the human genome. Cell129(4),823–837 (2007).
Medline CASGoogle Scholar
144 Mikkelsen TS, Ku M, Jaffe DB et al.: Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature448(7153),553–560 (2007).
Medline CASGoogle Scholar
145 Nossov V, Amneus M, Su F et al.: The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am. J. Obstet. Gynecol.199(3),215–223 (2008).
Medline CASGoogle Scholar
146 Bast RC Jr: Status of tumor markers in ovarian cancer screening. J. Clin. Oncol.21(Suppl. 10),200S–205S (2003).
MedlineGoogle Scholar
147 Hickey KP, Boyle KP, Jepps HM, Andrew AC, Buxton EJ, Burns PA: Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br. J. Cancer80(11),1803–1808 (1999).
Medline CASGoogle Scholar
148 Collins Y, Dicioccio R, Keitz B, Lele S, Odunsi K: Methylation of death-associated protein kinase in ovarian carcinomas. Int. J. Gynecol. Cancer16(Suppl. 1),195–199 (2006).
MedlineGoogle Scholar
149 Wiley A, Katsaros D, Fracchioli S, Yu H: Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int. J. Gynecol. Cancer16(1),210–218 (2006).
Medline CASGoogle Scholar
150 Wiley A, Katsaros D, Chen H et al.: Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer107(2),299–308 (2006).
Medline CASGoogle Scholar
151 Chan MW, Wei SH, Wen P et al.: Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin. Cancer Res.11(20),7376–7383 (2005).
Medline CASGoogle Scholar
152 Widschwendter M, Jiang G, Woods C et al.: DNA hypomethylation and ovarian cancer biology. Cancer Res.64(13),4472–4480 (2004).
Medline CASGoogle Scholar
153 Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH: An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int. J. Cancer124(2),387–393 (2009).
Medline CASGoogle Scholar
154 Apostolidou S, Hadwin R, Burnell M et al.: DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int. J. Cancer125(12),2995–3002 (2009).
Medline CASGoogle Scholar
155 Hoque MO, Begum S, Brait M et al.: Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J. Urol.179(2),743–747 (2008).
MedlineGoogle Scholar
156 Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer3(7),502–516 (2003).
Medline CASGoogle Scholar
157 Balch C, Huang TH, Brown R, Nephew KP: The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol.191(5),1552–1572 (2004).
Medline CASGoogle Scholar
158 Shah MA, Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res.7(8),2168–2181 (2001).
Medline CASGoogle Scholar
159 Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol.17(3),1061–1070 (1999).
Medline CASGoogle Scholar
160 Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene22(47),7265–7279 (2003).
Medline CASGoogle Scholar
161 Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE: Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer98(10),2199–2206 (2003).
Medline CASGoogle Scholar
162 Martini M, Ciccarone M, Garganese G et al.: Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int. J. Cancer102(4),398–406 (2002).
Medline CASGoogle Scholar
163 Jass JR, Walsh MD, Barker M, Simms LA, Young J, Leggett BA: Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur. J. Cancer38(7),858–866 (2002).
Medline CASGoogle Scholar
164 Wang L, Bani-Hani A, Montoya DP et al.: hMLH1 and hMSH2 expression in human hepatocellular carcinoma. Int. J. Oncol.19(3),567–570 (2001).
Medline CASGoogle Scholar
165 Atkin NB: Microsatellite instability. Cytogenet. Cell Genet.92(3–4),177–181 (2001).
Medline CASGoogle Scholar
166 Brown R, Hirst GL, Gallagher WM et al.: hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene15(1),45–52 (1997).
Medline CASGoogle Scholar
167 Liu L, Tommasi S, Lee DH, Dammann R, Pfeifer GP: Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene22(50),8125–8136 (2003).
Medline CASGoogle Scholar
168 Staub J, Chien J, Pan Y et al.: Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene26(34),4969–4978 (2007).
Medline CASGoogle Scholar
169 Lai J, Chien J, Staub J et al.: Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J. Biol. Chem.278(25),23107–23117 (2003).
Medline CASGoogle Scholar
170 Wei SH, Brown R, Huang TH: Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann. NY Acad. Sci.983,243–250 (2003).
Medline CASGoogle Scholar
171 Wei SH, Chen CM, Strathdee G et al.: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res.8(7),2246–2252 (2002).
Medline CASGoogle Scholar
172 Taniguchi T, Tischkowitz M, Ameziane N et al.: Disruption of the fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med.9(5),568–574 (2003).
Medline CASGoogle Scholar
173 Hatle KM, Neveu W, Dienz O et al.: Methylation-controlled J protein promotes c-Jun degradation to prevent ABCD1 transporter expression. Mol. Cell. Biol.27(8),2952–2966 (2007).
Medline CASGoogle Scholar
174 Shridhar V, Bible KC, Staub J et al.: Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res.61(10),4258–4265 (2001).
Medline CASGoogle Scholar
175 Strathdee G, Davies BR, Vass JK, Siddiqui N, Brown R: Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis25(5),693–701 (2004).
Medline CASGoogle Scholar
176 Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J, Brown R: Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol. Oncol.97(3),898–903 (2005).
Medline CASGoogle Scholar
177 Iorio MV, Visone R, Di Leva G et al.: MicroRNA signatures in human ovarian cancer. Cancer Res.67(18),8699–8707 (2007).▪ Evidences differential expression of miRNAs in ovarian cancer as well as its regulation by promoter methylation.
Medline CASGoogle Scholar
178 Yang H, Kong W, He L et al.: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res.68(2),425–433 (2008).
Medline CASGoogle Scholar
179 Yang N, Kaur S, Volinia S et al.: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res.68(24),10307–10314 (2008).
Medline CASGoogle Scholar
180 Boren T, Xiong Y, Hakam A et al.: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol. Oncol.113(2),249–255 (2009).
Medline CASGoogle Scholar
181 Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9),769–784 (2006).
Medline CASGoogle Scholar
182 Hellebrekers DM, Griffioen AW, Van Engeland M: Dual targeting of epigenetic therapy in cancer. Biochim. Biophys. Acta1775(1),76–91 (2007).
Medline CASGoogle Scholar
183 Kim TY, Bang YJ, Robertson KD: Histone deacetylase inhibitors for cancer therapy. Epigenetics1(1),14–23 (2006).
MedlineGoogle Scholar
184 Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer6(1),38–51 (2006).
Medline CASGoogle Scholar
185 Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell20(1),85–93 (1980).
Medline CASGoogle Scholar
186 Goffin J, Eisenhauer E: DNA methyltransferase inhibitors-state of the art. Ann. Oncol.13(11),1699–1716 (2002).
Medline CASGoogle Scholar
187 Cheng JC, Yoo CB, Weisenberger DJ et al.: Preferential response of cancer cells to zebularine. Cancer Cell6(2),151–158 (2004).
Medline CASGoogle Scholar
188 Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP: Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol.321(4),591–599 (2002).
Medline CASGoogle Scholar
189 Cheng JC, Matsen CB, Gonzales FA et al.: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl Cancer Inst.95(5),399–409 (2003).
Medline CASGoogle Scholar
190 Cheng JC, Weisenberger DJ, Gonzales FA et al.: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell. Biol.24(3),1270–1278 (2004).
Medline CASGoogle Scholar
191 Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R: Reversal of drug resistance in human tumor xenografts by 2´-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res.60(21),6039–6044 (2000).
Medline CASGoogle Scholar
192 Nguyen CT, Weisenberger DJ, Velicescu M et al.: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2´-deoxycytidine. Cancer Res.62(22),6456–6461 (2002).
Medline CASGoogle Scholar
193 Fahrner JA, Eguchi S, Herman JG, Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res.62(24),7213–7218 (2002).
Medline CASGoogle Scholar
194 Kondo Y, Shen L, Issa JP: Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol.23(1),206–215 (2003).
Medline CASGoogle Scholar
195 Zhang L, Volinia S, Bonome T et al.: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl Acad. Sci. USA105(19),7004–7009 (2008).
Medline CASGoogle Scholar
196 Brueckner B, Boy RG, Siedlecki P et al.: Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res.65(14),6305–6311 (2005).
Medline CASGoogle Scholar
197 Fang MZ, Wang Y, Ai N et al.: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res.63(22),7563–7570 (2003).
Medline CASGoogle Scholar
198 Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E et al.: Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res.9(5),1596–1603 (2003).
Medline CASGoogle Scholar
199 Villar-Garea A, Fraga MF, Espada J, Esteller M: Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res.63(16),4984–4989 (2003).
Medline CASGoogle Scholar
200 Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE: Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-α (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther.2(5),552–556 (2003).
Medline CASGoogle Scholar
201 Gartel AL, Serfas MS, Tyner AL: p21 – negative regulator of the cell cycle. Proc. Soc. Exp. Biol. Med.213(2),138–149 (1996).
Medline CASGoogle Scholar
202 Kelly WK, Marks PA: Drug insight: histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol.2(3),150–157 (2005).
Medline CASGoogle Scholar
203 Chen L, Fischle W, Verdin E, Greene WC: Duration of nuclear NF-κB action regulated by reversible acetylation. Science293(5535),1653–1657 (2001).
Medline CASGoogle Scholar
204 Costanzo A, Merlo P, Pediconi N et al.: DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell9(1),175–186 (2002).
Medline CASGoogle Scholar
205 Luo J, Su F, Chen D, Shiloh A, Gu W: Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature408(6810),377–381 (2000).
Medline CASGoogle Scholar
206 Yuan ZL, Guan YJ, Chatterjee D, Chin YE: STAT3 dimerization regulated by reversible acetylation of a single lysine residue. Science307(5707),269–273 (2005).
Medline CASGoogle Scholar
207 Dokmanovic M, Marks PA: Prospects: histone deacetylase inhibitors. J. Cell. Biochem.96(2),293–304 (2005).
Medline CASGoogle Scholar
208 Cimini D, Mattiuzzo M, Torosantucci L, Degrassi F: Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol. Biol. Cell14(9),3821–3833 (2003).
Medline CASGoogle Scholar
209 Blagosklonny MV, Robey R, Sackett DL et al.: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther.1(11),937–941 (2002).
Medline CASGoogle Scholar
210 Carducci MA, Gilbert J, Bowling MK et al.: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res.7(10),3047–3055 (2001).
Medline CASGoogle Scholar
211 Vigushin DM, Ali S, Pace PE et al.: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res.7(4),971–976 (2001).
Medline CASGoogle Scholar
212 Fouladi M, Furman WL, Chin T et al.: Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a children’s oncology group report. J. Clin. Oncol.24(22),3678–3685 (2006).
Medline CASGoogle Scholar
213 Klimek VM, Fircanis S, Maslak P et al.: Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res.14(3),826–832 (2008).
Medline CASGoogle Scholar
214 Kosugi H, Ito M, Yamamoto Y et al.: In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/Scid mice. Jpn J. Cancer Res.92(5),529–536 (2001).
Medline CASGoogle Scholar
215 Sasakawa Y, Naoe Y, Inoue T et al.: Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol.64(7),1079–1090 (2002).
Medline CASGoogle Scholar
216 Kelly WK, O’Connor OA, Krug LM et al.: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol.23(17),3923–3931 (2005).
Medline CASGoogle Scholar
217 O’connor OA, Heaney ML, Schwartz L et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol.24(1),166–173 (2006).
MedlineGoogle Scholar
218 Modesitt SC, Sill M, Hoffman JS, Bender DP: A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol. Oncol.109(2),182–186 (2008).
Medline CASGoogle Scholar
219 Garber K: HDAC inhibitors overcome first hurdle. Nat. Biotechnol.25(1),17–19 (2007).
Medline CASGoogle Scholar
220 Plumb JA, Finn PW, Williams RJ et al.: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther.2(8),721–728 (2003).
Medline CASGoogle Scholar
221 Qian X, Larochelle WJ, Ara G et al.: Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer Ther.5(8),2086–2095 (2006).
Medline CASGoogle Scholar
222 Steele NL, Plumb JA, Vidal L et al.: A Phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res.14(3),804–810 (2008).
Medline CASGoogle Scholar
223 Steele N, Finn P, Brown R, Plumb JA: Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer100(5),758–763 (2009).
Medline CASGoogle Scholar
224 Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet.21(1),103–107 (1999).
Medline CASGoogle Scholar
225 Anzai H, Frost P, Abbruzzese L: Synergistic cytotoxicity with 2´-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer Res.52(8),2180–2185 (1992).
Medline CASGoogle Scholar
226 Strathdee G, Mackean MJ, Illand M, Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene18(14),2335–2341 (1999).
Medline CASGoogle Scholar
227 Branch P, Masson M, Aquilina G, Bignami M, Karran P: Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene19(28),3138–3145 (2000).
Medline CASGoogle Scholar
228 Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol.4(6),351–358 (2003).
Medline CASGoogle Scholar
229 Bakkenist CJ, Kastan MB: DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature421(6922),499–506 (2003).
Medline CASGoogle Scholar
230 Thirlwell C, Eymard M, Feber A et al.: Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods (2010) (Epub ahead of print).
MedlineGoogle Scholar
231 Beck S, Rakyan VK: The methylome: approaches for global DNA methylation profiling. Trends Genet.24(5),231–237 (2008).
Medline CASGoogle Scholar
232 Thu KL, Pikor LA, Kennett JY, Alvarez CE, Lam WL: Methylation analysis by DNA immunoprecipitation. J. Cell. Physiol.222(3),522–531 (2010),
Medline CASGoogle Scholar
233 Rauch T, Pfeifer GP: Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab. Invest.85(9),1172–1180 (2005).
Medline CASGoogle Scholar
234 Bernstein BE, Kamal M, Lindblad-Toh K et al.: Genomic maps and comparative analysis of histone modifications in human and mouse. Cell120(2),169–181 (2005).
Medline CASGoogle Scholar
235 Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, Van Criekinge W: PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res.36(Database issue),D842–D846 (2008).
Medline CASGoogle Scholar
236 Strathdee G, Appleton K, Illand M et al.: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol.158(3),1121–1127 (2001).
Medline CASGoogle Scholar
237 Niederacher D, Yan HY, An HX, Bender HG, Beckmann MW: CDKN2a gene inactivation in epithelial sporadic ovarian cancer. Br. J. Cancer80(12),1920–1926 (1999).
Medline CASGoogle Scholar
238 Liu Z, Wang LE, Wang L et al.: Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin. Cancer Res.11(13),4968–4976 (2005).
Medline CASGoogle Scholar
239 Shivapurkar N, Toyooka S, Toyooka Ko et al.: Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int. J. Cancer109(5),786–792 (2004).
Medline CASGoogle Scholar
240 Cai LY, Abe M, Izumi S, Imura M, Yasugi T, Ushijima T: Identification of prtfdc1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers. Life sciences80(16),1458–1465 (2007).
Medline CASGoogle Scholar
241 Shen DH, Chan KY, Khoo US et al.: Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis26(4),855–863 (2005).
Medline CASGoogle Scholar
242 Czekierdowski A, Czekierdowska S, Szymanski M, Wielgos M, Kaminski P, Kotarski J: Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer. Neuro. Endocrinol. Lett.27(5),609–613 (2006).
Medline CASGoogle Scholar
243 Choi YL, Kang SY, Shin YK et al.: Aberrant hypermethylation of rassf1a promoter in ovarian borderline tumors and carcinomas. Virchows Arch.448(3),331–336 (2006).
Medline CASGoogle Scholar
244 Ma L, Zhang JH, Liu FR, Zhang X: Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors. Zhonghua Zhong Liu Za Zhi27(11),657–659 (2005).
Medline CASGoogle Scholar
245 Widschwendter A, Muller HM, Hubalek MM et al.: Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol. Oncol.93(2),407–416 (2004).
Medline CASGoogle Scholar
246 Okochi-Takada E, Nakazawa K, Wakabayashi M et al.: Silencing of the uchl1 gene in human colorectal and ovarian cancers. Int. J. Cancer119(6),1338–1344 (2006).
Medline CASGoogle Scholar
247 Kantarjian HM, O’Brien S, Cortes J et al.: Results of decitabine (5-aza-2´deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer98(3),522–528 (2003).
Medline CASGoogle Scholar
248 Tam KF, Liu VW, Liu SS et al.: Methylation profile in benign, borderline and malignant ovarian tumors. J. Cancer Res. Clin. Oncol.133(5),331–341 (2007).
Medline CASGoogle Scholar
249 Graham JS, Kaye SB, Brown R: The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer45(7),1129–1136 (2009).
Medline CASGoogle Scholar
250 Chuang JC, Yoo CB, Kwan JM et al.: Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2´-deoxycytidine. Mol. Cancer Ther.4(10),1515–1520 (2005).
Medline CASGoogle Scholar
251 Kattan MW, Shariat SF, Andrews B et al.: The addition of interleukin-6 soluble receptor and transforming growth factor-β1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J. Clin. Oncol.21(19),3573–3579 (2003).
Medline CASGoogle Scholar
252 Choan E, Segal R, Jonker D et al.: A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urologic Oncol.23(2),108–113 (2005).
Medline CASGoogle Scholar
253 Jatoi A, Ellison N, Burch PA et al.: A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer97(6),1442–1446 (2003).
Medline CASGoogle Scholar
254 Yung R, Chang S, Hemati N, Johnson K, Richardson B: Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum.40(8),1436–1443 (1997).
Medline CASGoogle Scholar
255 Mai A, Altucci L: Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol.41(1),199–213 (2009).
Medline CASGoogle Scholar
256 Butler KV, Kozikowski AP: Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Des.14(6),505–528 (2008).
Medline CASGoogle Scholar
257 Qian X, Ara G, Mills E, Larochelle WJ, Lichenstein HS, Jeffers M: Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int. J. Cancer122(6),1400–1410 (2008).
Medline CASGoogle Scholar
258 Hubbert C, Guardiola A, Shao R et al.: HDAC6 is a microtubule-associated deacetylase. Nature417(6887),455–458 (2002).
Medline CASGoogle Scholar
259 Marchion D, Munster P: Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther.7(4),583–598 (2007).
Medline CASGoogle Scholar
260 Dyer ES, Paulsen MT, Markwart SM, Goh M, Livant DL, Ljungman M: Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int. J. Cancer101(5),496–499 (2002).
Medline CASGoogle Scholar
261 Gore SD, Samid D, Weng LJ: Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res.3(10),1755–1762 (1997).
Medline CASGoogle Scholar
262 Melchior SW, Brown LG, Figg WD et al.: Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int. J. Oncol.14(3),501–508 (1999).
Medline CASGoogle Scholar
263 Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P, Ekstrom TJ: Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int. J. Oncol.22(3),579–588 (2003).
Medline CASGoogle Scholar
264 Gottlicher M, Minucci S, Zhu P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J.20(24),6969–6978 (2001).
Medline CASGoogle Scholar
265 Garcia-Manero G, Assouline S, Cortes J et al.: Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood112(4),981–989 (2008).
Medline CASGoogle Scholar
266 Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol.3,5– (2010).
MedlineGoogle Scholar
301 Clinical Trials (NIH) www.clinicaltrials.gov
Google Scholar

Vol. 4, No. 4

Metrics

Downloaded 213 times

History

Published online 11 August 2010

Published in print August 2010

Information

Keywords

Financial & competing interests disclosure

MO Hoque has received support from the Flight Attendant Medical Research Institute Young Clinical Scientist Award, International Association for the Study of Lung Cancer and Career development award from SPORE in Cervical Cancer Grants (NIH grant number p50 CA098252). MO Hoque is a paid consultant to Oncomethylome Sciences, SA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Epigenomics and ovarian carcinoma

Abstract

Bibliography